GlassScriptPhysician profile
James M Abroms
NPI 1013010164
$1,141.67
in general payments reported to CMS, 2019-2025
18 companies · $750 in 2025
The $750 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2024: $65.63 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $788 · Entertainment: $27.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.16 |
| Entertainment | $27.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $171.73 | 2019 | |
| Novo Nordisk INC | $159.68 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.17 | 2019-2025 | Xifaxan |
| Pfizer INC. | $137.23 | 2019-2025 | |
| Axsome Therapeutics, INC. | $123.59 | 2025 | Auvelity, Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $55.08 | 2025 | |
| Exact Sciences Corporation | $50.04 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $37.81 | 2025 | Mounjaro, Zepbound |
| Abbvie INC. | $36.71 | 2025 | |
| Merck Sharp & Dohme LLC | $35.41 | 2019-2025 | Capvaxive |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.48 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $29.89 | 2019-2025 | Farxiga |
| Optos, INC. | $27.04 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Astellas Pharma US INC | $26.87 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $25.90 | 2025 | Voquezna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $14.80 | 2025 | Nuzyra |
| Janssen Pharmaceuticals, INC | $13.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Abroms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.